title: Characterization of the anti-inflammatory effect of FK-506 on human mast cells.
abstract: We have examined the effects of FK-506 and of the struturally related macrolide rapamycin, which bind with high affinity to a specific binding protein (FKBP), to evaluate the involvement of this protein in the release of preformed (histamine) and de novo synthesized inflammatory mediators (sulfidopeptide leukotriene C4 and prostaglandin D2) from mast cells isolated from human lung parenchyma. FK-506 (0.1 to 300 nM) concentration dependently inhibited histamine release from lung parenchymal mast cells activated by anti-IgE. FK-506 was more potent in lung mast cells than in basophils (IC50 = 1.13 +/- 0.46 nM vs 5.28 +/- 0.88 nM; p less than 0.001), whereas the maximal inhibitory effect was higher in basophils than in lung mast cells (88.4 +/- 2.5% vs 76.4 +/- 3.8%; p less than 0.01). FK-506 had little or no inhibitory effect on histamine release from lung mast cells challenged with compound A23187, whereas it completely suppressed A23187-induced histamine release from basophils. FK-506 also inhibited the de novo synthesis of 5-lipoxygenase (sulfidopeptide leukotriene C4) and cyclo-oxygenase (prostaglandin D2) metabolites of arachidonic acid from mast cells challenged with anti-IgE. Unlike in basophils, Il-3 (3 to 30 ng/ml) did not modify anti-IgE- or A23187-induced histamine release from lung mast cells nor did it reverse the inhibitory effect of FK-506. Rapamycin (3 to 300 nM) had little or no effect on the release of histamine from lung mast cells, but it was a competitive antagonist of the inhibitory effect of FK-506 on anti-IgE-induced histamine release from human mast cells with a dissociation constant of about 12 nM. These data indicate that FK-506 is a potent anti-inflammatory agent that acts on human lung mast cells presumably by binding to a receptor site (i.e., FKBP).
authors.affiliation: Department of Medicine, University of Naples Federico II, Second School of Medicine, Italy.
authors.forename: A
authors.initials: A
authors.lastname: de Paulis
authors.forename: R
authors.initials: R
authors.lastname: Cirillo
authors.forename: A
authors.initials: A
authors.lastname: Ciccarelli
authors.forename: G
authors.initials: G
authors.lastname: de Crescenzo
authors.forename: A
authors.initials: A
authors.lastname: Oriente
authors.forename: G
authors.initials: G
authors.lastname: Marone
mesh_terms: D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology*; D016718:Arachidonic Acid / Q000378:metabolism; D001327:Autoimmune Diseases / Q000209:etiology; D000001:Calcimycin / Q000494:pharmacology; D002478:Cells, Cultured; D006636:Histamine Release / Q000187:drug effects; D006801:Humans; D007073:Immunoglobulin E / Q000276:immunology; D007377:Interleukin-3 / Q000494:pharmacology; D015289:Leukotrienes / Q000378:metabolism; D008407:Mast Cells / Q000187:drug effects*; D011090:Polyenes / Q000494:pharmacology; D020123:Sirolimus; D016559:Tacrolimus / Q000494:pharmacology* / Q000627:therapeutic use
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D007377:Interleukin-3; D015289:Leukotrienes; D011090:Polyenes; D016718:Arachidonic Acid; D007073:Immunoglobulin E; D000001:Calcimycin; D020123:Sirolimus; D016559:Tacrolimus